RebiSmart™ (version 1.5) device for multiple sclerosis treatment delivery and adherence
- 15 October 2012
- journal article
- research article
- Published by Informa Healthcare in Expert Opinion on Drug Delivery
- Vol. 10 (2) , 273-283
Abstract
Introduction: First-line disease-modifying drugs for the treatment of multiple sclerosis (MS) are mostly administered by injection. Although these treatments can control the symptoms and progression of the disease to some extent, patients often fail to adhere to their therapy in the long term, so may not obtain the maximum clinical benefits. As injection-related problems are common barriers to adherence, autoinjectors have been developed to improve the ease and convenience of self-injection. Areas covered: This article discusses RebiSmart™, an electronic autoinjector for the subcutaneous administration of interferon β-1a, focusing on the device features and data from clinical trials of the device. An overview of other available autoinjectors for first-line MS therapies is provided for context. Expert opinion: The device is the first electronic autoinjector for use in MS and offers several innovative features, including adjustable injection settings and an electronic dosing log, which may improve adherence...Keywords
This publication has 48 references indexed in Scilit:
- Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated SyndromePLOS ONE, 2012
- Adherence to Interferon β-1b Treatment in Patients with Multiple Sclerosis in SpainPLOS ONE, 2012
- Survival in MSNeurology, 2012
- Patient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV studyBMC Neurology, 2012
- The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational studyBMC Neurology, 2011
- Understanding and meeting injection device needs in multiple sclerosis: a survey of patient attitudes and practicesPatient Preference and Adherence, 2011
- Impact of exposure to interferon beta-1a on outcomes in patients with relapsing–remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up studyTherapeutic Advances in Neurological Disorders, 2011
- Evidence-based assessment of potential use of fingolimod in treatment of relapsing multiple sclerosisCore Evidence, 2011
- Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb studyBMC Neurology, 2010
- A novel needle for subcutaneous injection of interferon beta-1a: effect on pain in volunteers and satisfaction in patients with multiple sclerosisBMC Neurology, 2008